Natasia Courchesne-Krak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Natasia Courchesne-Krak has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Abraham A. Palmer
Department of Psychiatry, University of California San Diego
6 shared publications - Sandra Sanchez-Roige
Department of Medicine, Division of Genetic Medicine, Vanderbilt University Medical Center, Nashville, USA
6 shared publications - Carla Marienfeld
Department of Psychiatry, University of California San Diego, San Diego, USA
5 shared publications - Sarah N. Mattson
Center for Behavioral Teratology and Department of Psychology San Diego State University San Diego California USA
4 shared publications - Travis Triplett Mallard
Massachusetts General Hospital
4 shared publications - Danielle M. Dick
Rutgers University
3 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 56, e355
A phenome-wide association study of externalizing polygenic risk in the Adolescent Brain Cognitive Development (ABCD) study
Background: Externalizing disorders encompass a range of disinhibited behaviors that typically manifest in youth and are linked with adverse psychological and social outcomes. Polygenic liability to externalizing behaviors has been associated with psychiatric and disease phenotypes in adults. Identifying correlates of genetic risk in youth—prior to the emergence of more impairing manifestations of externalizing behaviors (e.g. substance use disorders)—could improve our etiological understanding and inform targeted prevention efforts. Methods: We conducted a phenome-wide association study (PheWAS) to test whether externalizing (EXT) polygenic scores (PGS) were associated with up to 1,697 psychosocial, behavioral, environmental, and health-related phenotypes among youth of European-like genetic ancestry. PheWAS data came from the baseline ( n = 4,931, mean age = 9.93 ± 0.63 years, 46.9% female) and two-year follow-up ( n = 4,507, 12.02 ± 0.66 years, 47.0% female) data collection waves of the Adolescent Brain Cognitive Development Study SM (ABCD Study®). Secondary analyses examined within-family effects and moderation by biological sex. Results: EXT PGS was associated with 268 and 352 phenotypes at baseline and follow-up, respectively, following Bonferroni correction at each wave. The strongest associations were observed with externalizing behaviors, screen time/media use, caffeine consumption, sleep disturbances, and poor school performance. Effects were attenuated by 59%–64% within family, on average, with five predominantly externalizing phenotypes remaining significantly associated with within-family PGS. There was limited evidence of moderation by biological sex. Conclusions: These results broadly characterize the early phenotypic correlates of an externalizing polygenic score and can be used to generate hypotheses about phenotypes that might represent mechanisms or future prevention targets.
- 5 November 2026
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 56, e355
Open AccessA phenome-wide association study of externalizing polygenic risk in the Adolescent Brain Cognitive Development (ABCD) study
Background: Externalizing disorders encompass a range of disinhibited behaviors that typically manifest in youth and are linked with adverse psychological and social outcomes. Polygenic liability to externalizing behaviors has been associated with psychiatric and disease phenotypes in adults. Identifying correlates of genetic risk in youth—prior to the emergence of more impairing manifestations of externalizing behaviors (e.g. substance use disorders)—could improve our etiological understanding and inform targeted prevention efforts. Methods: We conducted a phenome-wide association study (PheWAS) to test whether externalizing (EXT) polygenic scores (PGS) were associated with up to 1,697 psychosocial, behavioral, environmental, and health-related phenotypes among youth of European-like genetic ancestry. PheWAS data came from the baseline ( n = 4,931, mean age = 9.93 ± 0.63 years, 46.9% female) and two-year follow-up ( n = 4,507, 12.02 ± 0.66 years, 47.0% female) data collection waves of the Adolescent Brain Cognitive Development Study SM (ABCD Study®). Secondary analyses examined within-family effects and moderation by biological sex. Results: EXT PGS was associated with 268 and 352 phenotypes at baseline and follow-up, respectively, following Bonferroni correction at each wave. The strongest associations were observed with externalizing behaviors, screen time/media use, caffeine consumption, sleep disturbances, and poor school performance. Effects were attenuated by 59%–64% within family, on average, with five predominantly externalizing phenotypes remaining significantly associated with within-family PGS. There was limited evidence of moderation by biological sex. Conclusions: These results broadly characterize the early phenotypic correlates of an externalizing polygenic score and can be used to generate hypotheses about phenotypes that might represent mechanisms or future prevention targets.
- Open Access
Sex-Specific Genetic Architecture and Comorbidities of Alcohol Use Behaviors
Background: Sex differences in alcohol use behaviors are well-established: males typically engage in heavier and more frequent drinking and exhibit more externalizing behaviors (e.g., other substance use), while females often transition to dependence more rapidly and present more internalizing psychopathology (e.g., depression). The biological mechanisms underpinning these differences are relatively unknown. Methods: In this study, we investigated the sex-differentiated genetic architecture of 11 alcohol use phenotypes pertaining to frequency, quantity and problematic use by leveraging sex-stratified genome-wide association studies (Ns 40,335 to 613,148). Specifically, we compared SNP-based heritability ( h 2 SNP ) estimates, individual genetic locus effects, genetic correlations ( r g ) across alcohol phenotypes and with comorbid traits from independent GWAS, and polygenic score ( PGS ) associations with medical outcomes from clinical populations. Results: h 2 SNP was broadly similar between sexes, except for higher estimates in males for beer quantity and problematic alcohol use ( PAU ). We identified four sex-differentiated top loci ( p sex-diff < 5 x 10 -8 ), including a female-specific association in IZUMO1 for drinking frequency and quantity , and three male-specific associations in ADH1B , KLB and FTO for beer quantity and/or PAU . Between-sex genetic correlations ranged from 0.68±0.07 to 0.89±0.04, these estimates were lowest for quantity measures and varied by beverage type, indicating partially distinct polygenic architecture. In males, we identified stronger positive genetic correlations with several externalizing traits (e.g., general addiction) compared to females. In females, we identified a specific positive genetic correlation with a single internalizing trait, self-harm. PGS analyses revealed sex-specific medical associations (e.g., bone/musculoskeletal conditions in females; hepatic/respiratory/infectious sequelae in males) that were obscured in sex-combined analyses; however, sex-specific PGS did not outperform combined-sex PGS for predicting alcohol use disorder diagnosis. Conclusions: Sex-aware analyses of alcohol use behaviors can improve our understanding of the genetic etiology of alcohol use and related health outcomes, and future studies should consider cultural variation (e.g., drinking attitudes, social norms) in the relationship between behavior and genetics.
Open AccessSex-Specific Genetic Architecture and Comorbidities of Alcohol Use Behaviors
Background: Sex differences in alcohol use behaviors are well-established: males typically engage in heavier and more frequent drinking and exhibit more externalizing behaviors (e.g., other substance use), while females often transition to dependence more rapidly and present more internalizing psychopathology (e.g., depression). The biological mechanisms underpinning these differences are relatively unknown. Methods: In this study, we investigated the sex-differentiated genetic architecture of 11 alcohol use phenotypes pertaining to frequency, quantity and problematic use by leveraging sex-stratified genome-wide association studies (Ns 40,335 to 613,148). Specifically, we compared SNP-based heritability ( h 2 SNP ) estimates, individual genetic locus effects, genetic correlations ( r g ) across alcohol phenotypes and with comorbid traits from independent GWAS, and polygenic score ( PGS ) associations with medical outcomes from clinical populations. Results: h 2 SNP was broadly similar between sexes, except for higher estimates in males for beer quantity and problematic alcohol use ( PAU ). We identified four sex-differentiated top loci ( p sex-diff < 5 x 10 -8 ), including a female-specific association in IZUMO1 for drinking frequency and quantity , and three male-specific associations in ADH1B , KLB and FTO for beer quantity and/or PAU . Between-sex genetic correlations ranged from 0.68±0.07 to 0.89±0.04, these estimates were lowest for quantity measures and varied by beverage type, indicating partially distinct polygenic architecture. In males, we identified stronger positive genetic correlations with several externalizing traits (e.g., general addiction) compared to females. In females, we identified a specific positive genetic correlation with a single internalizing trait, self-harm. PGS analyses revealed sex-specific medical associations (e.g., bone/musculoskeletal conditions in females; hepatic/respiratory/infectious sequelae in males) that were obscured in sex-combined analyses; however, sex-specific PGS did not outperform combined-sex PGS for predicting alcohol use disorder diagnosis. Conclusions: Sex-aware analyses of alcohol use behaviors can improve our understanding of the genetic etiology of alcohol use and related health outcomes, and future studies should consider cultural variation (e.g., drinking attitudes, social norms) in the relationship between behavior and genetics.
- 1 January 2025
- Published by S. Karger AG in Complex Psychiatry
- Vol. 11 (1) , 72-93
Prescription Opioid Medication Survey: A Tool to Collect Deep Phenotypic Data on the Multifactorial Pathways to Opioid Use Disorder in Clinical and Population-Based Cohorts
Introduction: We are in the midst of an opioid epidemic. In the USA, more than a third of the country knows someone who has died from an opioid overdose. Prescription opioids (e.g., oxycodone, hydrocodone, and fentanyl) are commonly used and misused, and it has been estimated that approximately 8–12% of individuals who misuse opioids will subsequently develop an opioid use disorder (OUD). While emphasis has been placed on understanding OUD and the associated adverse effects, there remains a critical gap in systematically characterizing the multifactorial pathways (e.g., behavioral, clinical, genetic, and socio-demographic characteristics) that contribute to the transition from initial use to misuse to OUD. Methods: To address this gap, we introduce the Prescription Opioid Medication Survey (POMS), an online 120-item assessment that compiles multiple validated and standardized instruments. POMS is intended for individuals with any lifetime prescription opioid use. POMS captures various aspects of prescription opioid use including data on opioid use patterns, subjective effects (e.g., euphoria, nausea), problematic use, withdrawal, OUD, overdose, treatment history, and remission. It also addresses comorbid risk factors such as surgical history, chronic pain, other substance use disorders (SUD; e.g., nicotine, alcohol, cannabis, stimulants), other addictive behaviors (i.e., gambling, sexual behaviors, and gaming), and family history of SUD and other addictive behaviors. Mental health assessments, including screening for depression and anxiety, self-reports of eight psychiatric disorders (anxiety, depression, bipolar, schizophrenia, attention-deficit/hyperactivity disorder, post-traumatic stress disorder, obsessive-compulsive disorder, eating disorders), and related mental health conditions (e.g., loneliness, suicide, trauma) are included, along with data on personality traits (e.g., risk-taking, delay discounting, wisdom) and socio-demographic factors. POMS is intended to be administered in clinical settings and large population-based cohorts, facilitating data collection that can enable discoveries to inform better prevention and intervention strategies for OUD. Conclusion: POMS offers a comprehensive tool for systematically capturing the multifactorial risk factors associated with opioid misuse and OUD, providing insights that can inform prevention and intervention strategies.
- 1 January 2025
- Published by S. Karger AG in Complex Psychiatry
- Vol. 11 (1) , 72-93
Prescription Opioid Medication Survey: A Tool to Collect Deep Phenotypic Data on the Multifactorial Pathways to Opioid Use Disorder in Clinical and Population-Based Cohorts
Introduction: We are in the midst of an opioid epidemic. In the USA, more than a third of the country knows someone who has died from an opioid overdose. Prescription opioids (e.g., oxycodone, hydrocodone, and fentanyl) are commonly used and misused, and it has been estimated that approximately 8–12% of individuals who misuse opioids will subsequently develop an opioid use disorder (OUD). While emphasis has been placed on understanding OUD and the associated adverse effects, there remains a critical gap in systematically characterizing the multifactorial pathways (e.g., behavioral, clinical, genetic, and socio-demographic characteristics) that contribute to the transition from initial use to misuse to OUD. Methods: To address this gap, we introduce the Prescription Opioid Medication Survey (POMS), an online 120-item assessment that compiles multiple validated and standardized instruments. POMS is intended for individuals with any lifetime prescription opioid use. POMS captures various aspects of prescription opioid use including data on opioid use patterns, subjective effects (e.g., euphoria, nausea), problematic use, withdrawal, OUD, overdose, treatment history, and remission. It also addresses comorbid risk factors such as surgical history, chronic pain, other substance use disorders (SUD; e.g., nicotine, alcohol, cannabis, stimulants), other addictive behaviors (i.e., gambling, sexual behaviors, and gaming), and family history of SUD and other addictive behaviors. Mental health assessments, including screening for depression and anxiety, self-reports of eight psychiatric disorders (anxiety, depression, bipolar, schizophrenia, attention-deficit/hyperactivity disorder, post-traumatic stress disorder, obsessive-compulsive disorder, eating disorders), and related mental health conditions (e.g., loneliness, suicide, trauma) are included, along with data on personality traits (e.g., risk-taking, delay discounting, wisdom) and socio-demographic factors. POMS is intended to be administered in clinical settings and large population-based cohorts, facilitating data collection that can enable discoveries to inform better prevention and intervention strategies for OUD. Conclusion: POMS offers a comprehensive tool for systematically capturing the multifactorial risk factors associated with opioid misuse and OUD, providing insights that can inform prevention and intervention strategies.
- Open Access
- 23 November 2024
- Published by Elsevier in Addictive Behaviors Reports
- Vol. 20, 100573
Emergency care utilization in persons with substance related diagnoses
- 23 November 2024
- Published by Elsevier in Addictive Behaviors Reports
- Vol. 20, 100573
Open AccessEmergency care utilization in persons with substance related diagnoses
- 11 June 2024
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 49 (10) , 1609-1618
Genome-wide association studies of coffee intake in UK/US participants of European ancestry uncover cohort-specific genetic associations
Coffee is one of the most widely consumed beverages. We performed a genome-wide association study (GWAS) of coffee intake in US-based 23andMe participants (N = 130,153) and identified 7 significant loci, with many replicating in three multi-ancestral cohorts. We examined genetic correlations and performed a phenome-wide association study across hundreds of biomarkers, health, and lifestyle traits, then compared our results to the largest available GWAS of coffee intake from the UK Biobank (UKB; N = 334,659). We observed consistent positive genetic correlations with substance use and obesity in both cohorts. Other genetic correlations were discrepant, including positive genetic correlations between coffee intake and psychiatric illnesses, pain, and gastrointestinal traits in 23andMe that were absent or negative in the UKB, and genetic correlations with cognition that were negative in 23andMe but positive in the UKB. Phenome-wide association study using polygenic scores of coffee intake derived from 23andMe or UKB summary statistics also revealed consistent associations with increased odds of obesity- and red blood cell-related traits, but all other associations were cohort-specific. Our study shows that the genetics of coffee intake associate with substance use and obesity across cohorts, but also that GWAS performed in different populations could capture cultural differences in the relationship between behavior and genetics.
- 11 June 2024
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 49 (10) , 1609-1618
Genome-wide association studies of coffee intake in UK/US participants of European ancestry uncover cohort-specific genetic associations
Coffee is one of the most widely consumed beverages. We performed a genome-wide association study (GWAS) of coffee intake in US-based 23andMe participants (N = 130,153) and identified 7 significant loci, with many replicating in three multi-ancestral cohorts. We examined genetic correlations and performed a phenome-wide association study across hundreds of biomarkers, health, and lifestyle traits, then compared our results to the largest available GWAS of coffee intake from the UK Biobank (UKB; N = 334,659). We observed consistent positive genetic correlations with substance use and obesity in both cohorts. Other genetic correlations were discrepant, including positive genetic correlations between coffee intake and psychiatric illnesses, pain, and gastrointestinal traits in 23andMe that were absent or negative in the UKB, and genetic correlations with cognition that were negative in 23andMe but positive in the UKB. Phenome-wide association study using polygenic scores of coffee intake derived from 23andMe or UKB summary statistics also revealed consistent associations with increased odds of obesity- and red blood cell-related traits, but all other associations were cohort-specific. Our study shows that the genetics of coffee intake associate with substance use and obesity across cohorts, but also that GWAS performed in different populations could capture cultural differences in the relationship between behavior and genetics.
- Open Access
- 8 November 2023
- Published by Springer Nature in Discover Mental Health
- Vol. 3 (1) , 1-8
Craving among patients seeking treatment for substance use disorder
Background Craving has been implicated as a central feature of addiction and a predictor of relapse. However, a complete understanding of how craving varies across patient populations is lacking. This study aimed to better inform the effective and accurate use of craving as a clinical prognostic tool for patients with substance use disorders (SUD). Methods This cross-sectional study utilized information gathered on patients (n = 112) entering specialty treatment for a SUD. Craving in the prior 30 days was assessed with a single item with other intake questionnaires. Results Patients who reported substance use in the last 30 days were more likely to report craving compared to patients who did not report substance use in the last 30 days (AOR = 6.86 [95% CI 2.17–21.7], p-value = 0.001). Patients who reported Hispanic/Latinx ethnicity were less likely to report craving compared to patients who did not report Hispanic/Latinx ethnicity (AOR = 0.28 [95% CI 0.08–0.95], p-value = 0.04). There was no association between craving and Adverse Childhood Events (OR = 1.03 [95% CI 0.84–1.25], p-value = 0.81). Conclusion The association between recent substance use and craving supports previous findings. The observed variation in craving among patients who report Hispanic/Latinx ethnicity is novel and suggests socio-cultural influences and possibly genetic factors influencing reported craving amongst patients. Additional research is needed to further understand the underlying factors leading to this finding, in order for better utilization of craving as a clinical indicator across patient populations.
- 8 November 2023
- Published by Springer Nature in Discover Mental Health
- Vol. 3 (1) , 1-8
Open AccessCraving among patients seeking treatment for substance use disorder
Background Craving has been implicated as a central feature of addiction and a predictor of relapse. However, a complete understanding of how craving varies across patient populations is lacking. This study aimed to better inform the effective and accurate use of craving as a clinical prognostic tool for patients with substance use disorders (SUD). Methods This cross-sectional study utilized information gathered on patients (n = 112) entering specialty treatment for a SUD. Craving in the prior 30 days was assessed with a single item with other intake questionnaires. Results Patients who reported substance use in the last 30 days were more likely to report craving compared to patients who did not report substance use in the last 30 days (AOR = 6.86 [95% CI 2.17–21.7], p-value = 0.001). Patients who reported Hispanic/Latinx ethnicity were less likely to report craving compared to patients who did not report Hispanic/Latinx ethnicity (AOR = 0.28 [95% CI 0.08–0.95], p-value = 0.04). There was no association between craving and Adverse Childhood Events (OR = 1.03 [95% CI 0.84–1.25], p-value = 0.81). Conclusion The association between recent substance use and craving supports previous findings. The observed variation in craving among patients who report Hispanic/Latinx ethnicity is novel and suggests socio-cultural influences and possibly genetic factors influencing reported craving amongst patients. Additional research is needed to further understand the underlying factors leading to this finding, in order for better utilization of craving as a clinical indicator across patient populations.
- Open Access
- 29 September 2023
- Published by Yale Journal of Biology and Medicine in The Yale Journal of Biology and Medicine
- Vol. 96 (3) , 277-291
What Brings You in Today? Sex, Race, Substance Type, and Other Sociodemographic and Health-Related Characteristics Predict if Substance Use is the Main Reason for a Clinical Encounter
Background: Substance-related diagnoses (SRDs) are a common healthcare presentation. This study identified sociodemographic and health-related characteristics associated with having an SRD as the primary reason for a clinical encounter compared to those ...
- 29 September 2023
- Published by Yale Journal of Biology and Medicine in The Yale Journal of Biology and Medicine
- Vol. 96 (3) , 277-291
Open AccessWhat Brings You in Today? Sex, Race, Substance Type, and Other Sociodemographic and Health-Related Characteristics Predict if Substance Use is the Main Reason for a Clinical Encounter
Background: Substance-related diagnoses (SRDs) are a common healthcare presentation. This study identified sociodemographic and health-related characteristics associated with having an SRD as the primary reason for a clinical encounter compared to those ...
- Open Access
- 15 September 2023
- Published by Springer Nature in Behavior Genetics
- Vol. 53 (5-6) , 404-415
Guidelines for Evaluating the Comparability of Down-Sampled GWAS Summary Statistics
Proprietary genetic datasets are valuable for boosting the statistical power of genome-wide association studies (GWASs), but their use can restrict investigators from publicly sharing the resulting summary statistics. Although researchers can resort to sharing down-sampled versions that exclude restricted data, down-sampling reduces power and might change the genetic etiology of the phenotype being studied. These problems are further complicated when using multivariate GWAS methods, such as genomic structural equation modeling (Genomic SEM), that model genetic correlations across multiple traits. Here, we propose a systematic approach to assess the comparability of GWAS summary statistics that include versus exclude restricted data. Illustrating this approach with a multivariate GWAS of an externalizing factor, we assessed the impact of down-sampling on (1) the strength of the genetic signal in univariate GWASs, (2) the factor loadings and model fit in multivariate Genomic SEM, (3) the strength of the genetic signal at the factor level, (4) insights from gene-property analyses, (5) the pattern of genetic correlations with other traits, and (6) polygenic score analyses in independent samples. For the externalizing GWAS, although down-sampling resulted in a loss of genetic signal and fewer genome-wide significant loci; the factor loadings and model fit, gene-property analyses, genetic correlations, and polygenic score analyses were found robust. Given the importance of data sharing for the advancement of open science, we recommend that investigators who generate and share down-sampled summary statistics report these analyses as accompanying documentation to support other researchers’ use of the summary statistics.
- 15 September 2023
- Published by Springer Nature in Behavior Genetics
- Vol. 53 (5-6) , 404-415
Open AccessGuidelines for Evaluating the Comparability of Down-Sampled GWAS Summary Statistics
Proprietary genetic datasets are valuable for boosting the statistical power of genome-wide association studies (GWASs), but their use can restrict investigators from publicly sharing the resulting summary statistics. Although researchers can resort to sharing down-sampled versions that exclude restricted data, down-sampling reduces power and might change the genetic etiology of the phenotype being studied. These problems are further complicated when using multivariate GWAS methods, such as genomic structural equation modeling (Genomic SEM), that model genetic correlations across multiple traits. Here, we propose a systematic approach to assess the comparability of GWAS summary statistics that include versus exclude restricted data. Illustrating this approach with a multivariate GWAS of an externalizing factor, we assessed the impact of down-sampling on (1) the strength of the genetic signal in univariate GWASs, (2) the factor loadings and model fit in multivariate Genomic SEM, (3) the strength of the genetic signal at the factor level, (4) insights from gene-property analyses, (5) the pattern of genetic correlations with other traits, and (6) polygenic score analyses in independent samples. For the externalizing GWAS, although down-sampling resulted in a loss of genetic signal and fewer genome-wide significant loci; the factor loadings and model fit, gene-property analyses, genetic correlations, and polygenic score analyses were found robust. Given the importance of data sharing for the advancement of open science, we recommend that investigators who generate and share down-sampled summary statistics report these analyses as accompanying documentation to support other researchers’ use of the summary statistics.
- Open Access
Genome-Wide Association Studies of Coffee Intake in UK/US Participants of European Ancestry Uncover Gene-Cohort Influences
Coffee is one of the most widely consumed beverages. We performed a genome-wide association study ( GWAS ) of coffee intake in US-based 23andMe participants ( N =130,153) and identified 7 significant loci, with many replicating in three multi-ancestral cohorts. We examined genetic correlations and performed a phenome-wide association study across thousands of biomarkers and health and lifestyle traits, then compared our results to the largest available GWAS of coffee intake from UK Biobank (UKB; N =334,659). The results of these two GWAS were highly discrepant. We observed positive genetic correlations between coffee intake and psychiatric illnesses, pain, and gastrointestinal traits in 23andMe that were absent or negative in UKB. Genetic correlations with cognition were negative in 23andMe but positive in UKB. The only consistent observations were positive genetic correlations with substance use and obesity. Our study shows that GWAS in different cohorts could capture cultural differences in the relationship between behavior and genetics.
Open AccessGenome-Wide Association Studies of Coffee Intake in UK/US Participants of European Ancestry Uncover Gene-Cohort Influences
Coffee is one of the most widely consumed beverages. We performed a genome-wide association study ( GWAS ) of coffee intake in US-based 23andMe participants ( N =130,153) and identified 7 significant loci, with many replicating in three multi-ancestral cohorts. We examined genetic correlations and performed a phenome-wide association study across thousands of biomarkers and health and lifestyle traits, then compared our results to the largest available GWAS of coffee intake from UK Biobank (UKB; N =334,659). The results of these two GWAS were highly discrepant. We observed positive genetic correlations between coffee intake and psychiatric illnesses, pain, and gastrointestinal traits in 23andMe that were absent or negative in UKB. Genetic correlations with cognition were negative in 23andMe but positive in UKB. The only consistent observations were positive genetic correlations with substance use and obesity. Our study shows that GWAS in different cohorts could capture cultural differences in the relationship between behavior and genetics.
- 20 July 2023
- Published by Springer Nature
- p. 221-240
Neuropsychological Outcomes in FASD Across the Lifespan
- 20 July 2023
- Published by Springer Nature
- p. 221-240
Neuropsychological Outcomes in FASD Across the Lifespan